Tags

Type your tag names separated by a space and hit enter

Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Ophthalmology 2014; 121(11):2181-92O

Abstract

OBJECTIVE

To evaluate the 24-month efficacy and safety of intravitreal ranibizumab 0.5 mg and 2.0 mg administered monthly or as needed (pro re nata [PRN]) in patients with neovascular age-related macular degeneration (wet AMD).

DESIGN

Twenty-four-month, multicenter, randomized, double-masked, active treatment-controlled phase 3 trial.

PARTICIPANTS

Patients (n = 1098) ≥ 50 years of age with treatment-naïve subfoveal wet AMD.

METHODS

Patients were randomized to receive intravitreal injections of ranibizumab 0.5 mg or 2.0 mg monthly or PRN after 3 monthly loading doses.

MAIN OUTCOME MEASURES

The primary efficacy end point was the mean change in best-corrected visual acuity (BCVA) from baseline at month 12. Key secondary end points included mean change in BCVA from baseline at month 24, proportion of patients who gained ≥ 15 letters in BCVA, mean number of ranibizumab injections, and mean change in central foveal thickness from baseline over time by spectral-domain optical coherence tomography. Ocular and systemic safety events also were evaluated through month 24.

RESULTS

At month 24, the mean change from baseline in BCVA was (letters) +9.1 (0.5 mg monthly), +7.9 (0.5 mg PRN), +8.0 (2.0 mg monthly), and +7.6 (2.0 mg PRN). The change in mean BCVA from month 12 to 24 was (letters) -1.0, -0.3, -1.2, and -1.0, respectively. The proportion of patients who gained ≥ 15 letters from baseline in BCVA at month 24 was 34.5%, 33.1%, 37.6%, and 34.8%, respectively. The mean number of ranibizumab injections through month 24 was 21.4, 13.3, 21.6, and 11.2, respectively; 5.6 and 4.3 mean injections were required in year 2 in the 0.5 mg and 2.0 mg PRN groups, respectively. The average treatment interval in the 0.5 mg PRN group was 9.9 weeks after 3 monthly loading doses, and 93% of these patients did not require monthly dosing. Ocular and systemic safety profiles over 2 years were similar among all 4 treatment groups and were consistent with previous ranibizumab trials in AMD.

CONCLUSIONS

At month 24, mean BCVA improvements were clinically meaningful and similar among all 4 ranibizumab treatment groups. The 0.5 mg PRN group achieved a mean gain of 7.9 letters at month 24 with an average of 13.3 injections (5.6 injections in year 2). No new safety events were identified over 24 months.

Authors+Show Affiliations

Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania. Electronic address: acho@att.net.Tennessee Retina, Nashville, Tennessee.Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania.Northern California Retina Vitreous Associates, Mountain View, California.Genentech, Inc., South San Francisco, California.Genentech, Inc., South San Francisco, California.Genentech, Inc., South San Francisco, California.Genentech, Inc., South San Francisco, California.No affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25015215

Citation

Ho, Allen C., et al. "Twenty-four-month Efficacy and Safety of 0.5 Mg or 2.0 Mg Ranibizumab in Patients With Subfoveal Neovascular Age-related Macular Degeneration." Ophthalmology, vol. 121, no. 11, 2014, pp. 2181-92.
Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181-92.
Ho, A. C., Busbee, B. G., Regillo, C. D., Wieland, M. R., Van Everen, S. A., Li, Z., ... Lai, P. (2014). Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology, 121(11), pp. 2181-92. doi:10.1016/j.ophtha.2014.05.009.
Ho AC, et al. Twenty-four-month Efficacy and Safety of 0.5 Mg or 2.0 Mg Ranibizumab in Patients With Subfoveal Neovascular Age-related Macular Degeneration. Ophthalmology. 2014;121(11):2181-92. PubMed PMID: 25015215.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. AU - Ho,Allen C, AU - Busbee,Brandon G, AU - Regillo,Carl D, AU - Wieland,Mark R, AU - Van Everen,Sherri A, AU - Li,Zhengrong, AU - Rubio,Roman G, AU - Lai,Phillip, AU - ,, Y1 - 2014/07/09/ PY - 2013/11/21/received PY - 2014/01/07/revised PY - 2014/04/08/accepted PY - 2014/7/13/entrez PY - 2014/7/13/pubmed PY - 2015/3/27/medline SP - 2181 EP - 92 JF - Ophthalmology JO - Ophthalmology VL - 121 IS - 11 N2 - OBJECTIVE: To evaluate the 24-month efficacy and safety of intravitreal ranibizumab 0.5 mg and 2.0 mg administered monthly or as needed (pro re nata [PRN]) in patients with neovascular age-related macular degeneration (wet AMD). DESIGN: Twenty-four-month, multicenter, randomized, double-masked, active treatment-controlled phase 3 trial. PARTICIPANTS: Patients (n = 1098) ≥ 50 years of age with treatment-naïve subfoveal wet AMD. METHODS: Patients were randomized to receive intravitreal injections of ranibizumab 0.5 mg or 2.0 mg monthly or PRN after 3 monthly loading doses. MAIN OUTCOME MEASURES: The primary efficacy end point was the mean change in best-corrected visual acuity (BCVA) from baseline at month 12. Key secondary end points included mean change in BCVA from baseline at month 24, proportion of patients who gained ≥ 15 letters in BCVA, mean number of ranibizumab injections, and mean change in central foveal thickness from baseline over time by spectral-domain optical coherence tomography. Ocular and systemic safety events also were evaluated through month 24. RESULTS: At month 24, the mean change from baseline in BCVA was (letters) +9.1 (0.5 mg monthly), +7.9 (0.5 mg PRN), +8.0 (2.0 mg monthly), and +7.6 (2.0 mg PRN). The change in mean BCVA from month 12 to 24 was (letters) -1.0, -0.3, -1.2, and -1.0, respectively. The proportion of patients who gained ≥ 15 letters from baseline in BCVA at month 24 was 34.5%, 33.1%, 37.6%, and 34.8%, respectively. The mean number of ranibizumab injections through month 24 was 21.4, 13.3, 21.6, and 11.2, respectively; 5.6 and 4.3 mean injections were required in year 2 in the 0.5 mg and 2.0 mg PRN groups, respectively. The average treatment interval in the 0.5 mg PRN group was 9.9 weeks after 3 monthly loading doses, and 93% of these patients did not require monthly dosing. Ocular and systemic safety profiles over 2 years were similar among all 4 treatment groups and were consistent with previous ranibizumab trials in AMD. CONCLUSIONS: At month 24, mean BCVA improvements were clinically meaningful and similar among all 4 ranibizumab treatment groups. The 0.5 mg PRN group achieved a mean gain of 7.9 letters at month 24 with an average of 13.3 injections (5.6 injections in year 2). No new safety events were identified over 24 months. SN - 1549-4713 UR - https://www.unboundmedicine.com/medline/citation/25015215/Twenty_four_month_efficacy_and_safety_of_0_5_mg_or_2_0_mg_ranibizumab_in_patients_with_subfoveal_neovascular_age_related_macular_degeneration_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(14)00429-1 DB - PRIME DP - Unbound Medicine ER -